The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection

Clinical Interventions in Aging

Volumn 8, Issue , 2013, Pages 149-156

  Duplancic, Darko ^a   Cesarik, Marijan ^b   Poljak, Nikola Kolja ^a   Radman, Maja ^a   Kovacic, Vedran ^a   Radic, Josipa ^a   Rogosic, Veljko ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b General Hospital Pozega   (Croatia)

Author keywords

Albuminuria; Cardiovascular system; Inflammation; Vitamin D deficiency

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCITRIOL; CALCIUM; COLECALCIFEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXERCALCIFEROL; ENALAPRIL; LOSARTAN; PARICALCITOL; VITAMIN D; VITAMIN D RECEPTOR;

ALBUMINURIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD VESSEL CALCIFICATION; CARDIORENAL SYNDROME; CARDIOVASCULAR SYSTEM; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; DIABETIC NEPHROPATHY; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; IMMUNOMODULATION; KIDNEY FAILURE; KIDNEY INJURY; LOW DRUG DOSE; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR UPREGULATION; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY HYPERPARATHYROIDISM; SIGNAL TRANSDUCTION; TREATMENT DURATION; UREMIA; VITAMIN D DEFICIENCY;

ALBUMINURIA; CARDIOVASCULAR SYSTEM; INFLAMMATION; VITAMIN D DEFICIENCY;

AGING; ANIMALS; BONE DENSITY CONSERVATION AGENTS; CARDIO-RENAL SYNDROME; CARDIOVASCULAR SYSTEM; CHRONIC DISEASE; ERGOCALCIFEROLS; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CALCITRIOL; RENAL INSUFFICIENCY, CHRONIC;

EID: 84873691058     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S38349     Document Type: Review

References (76)

1. Webb RA. Who, what, where and when-influences on cutaneous vitamin D synthesis. Prog Biophys Mol Biol. 2006;92:17-25.
2. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289:8-28.
3. Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: A review. Altern Med Rev. 2005;10:94-111.
4. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85:1586-1591.
5. Gouni-Berthold I, Krone W, Berthold HK. Vitamin D and cardiovascular disease. Curr Vasc Pharmacol. 2009;7:414-422.
6. Parker J, Hashmi O, Dutton D, et al. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas. 2010;65:225-236.
7. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens. 2007;20:713-719.
8. Freedman BI, Wagenknecht LE, Hairston KG, et al. Vitamin D, adiposity, and calcified atherosclerotic plaque in African-Americans. J Clin Endocrinol Metab. 2010;95:1076-1083.
9. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80(Suppl 6):S1689-S1696.
10. Mitsuhashi T, Morris RC Jr, Ives HE. 1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest. 1991;87:1889-1895.
11. Michos ED, Melamed ML. Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care. 2008;11:7-12.
12. Panichi V, De Pietro S, Andreini B, et al. Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int. 1998;54:1463-1469.
13. Bellows CG, Reimers SM, Heersche JN. Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3. Cell Tissue Res. 1999;297:249-259.
14. Drissi H, Pouliot A, Koolloos C, et al. 1,25-(OH)2-vitamin D3suppresses the bone-related Runx2/Cbfa1gene promoter. Exp Cell Res. 2002;274:323-333.
15. Aihara K, Azuma H, Akaike M, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem. 2004;279:35798-35802.
16. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol. 2007;103:521-524.
17. Meems LM, van der Harst P, van Gilst WH, de Boer RA. Vitamin D biology in heart failure: molecular mechanisms and systematic review. Curr Drug Targets. 2011;12:29-41.
18. Talmor Y, Golan E, Benchetrit S, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol. 2008;294:1059-1064.
19. Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation. 2007;115:846-854.
20. Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr. 2009;89:1321-1327.
21. Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:1931-1942.
22. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167(16):1730-1737.
23. Dobnig H, Pilz S, Scharnagl H, Renner W, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168:1340-1349.
24. Inaguma D, Nagaya H, Hara K, et al. Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease. Clin Exp Nephrol. 2008;12:126-131.
25. Baker LR, Abrams L, Roe CJ, et al. 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int. 1989;35:661-669.
26. Moe SM, Drüeke TB, Block GA, et al. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1-S130.
27. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69:1945-1953.
28. Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997;96:1755-1760.
29. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16:1115-1125.
30. Bianchi ML, Colantonio G, Campanini F, et al. Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant. 1994;9:1595-1599.
31. Yildiz A, Memisoglu E, Oflaz H, et al. Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic haemodialysis patients. Nephrol Dial Transplant. 2005;20:760-767.
32. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol. 2003;9 Suppl 4:S305-S309.
33. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112-S119.
34. [No authors listed]. VI. Causes of death in ESRD. Am J Kidney Dis. 1999;34(2 Suppl 1):S87-S94.
35. [No authors listed]. V. Patient mortality and survival in ESRD. Am J Kidney Dis. 1999;34:(2 Suppl 1):S74-S86.
36. Goodman WG, Coburn JW. The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med. 1992;43:227-237.
37. Demer LL, Tintut Y. Vascular calcification: pathobiology of multifaceted disease. Circulation. 2008;117:2938-2948.
38. Bas A, Lopez I, Perez J, Rodriguez M, Aguilera-Tejero E. Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res. 2006;21:484-490.
39. Stubbs JR, Liu S, Tang W, et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007;18:2116-2124.
40. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int. 2005;68:429-436.
41. Brown AJ, Finch J, Takahashi F, Slatopolsky E. Calcemic activity of 19-Nor-1,25(OH)(2)D(2) decreases with duration of treatment. J Am Soc Nephrol. 2000;11:2088-2094.
42. Mizobuchi M, Ogata H, Koiwa F, Kinugasa E, Akizawa T. Vitamin D and vascular calcification in chronic kidney disease. Bone. 2009; 45 Suppl 1:S26-S29.
43. Andress D. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs. 2007;67:1999-2012.
44. Cheng J, Zhang W, Zhang X, Li X, Chen J. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2012;7:391-400.
45. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63:1483-1490.
46. Brown JA, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphate transport. J Lab Clin Med. 2002;139:279-284.
47. Nakane M, Ma J, Rose AE, et al. Differential effects of vitamin D analogs on calcium transport. J Steroid Biochem Mol Biol. 2007;103:84-89.
48. Sprague SM, Lerma E, McCormmick D, et al. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis. 2001;38:S51-S56.
49. Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis. 1997;30:105-112.
50. Rodriguez M, Martinez-Moreno JM, Rodríguez-Ortiz ME, Muñoz-Castañeda JR, Almaden Y. Vitamin D and vascular calcification in chronic kidney disease. Kidney Blood Press Res. 2011;34:261-268.
51. Li X, Speer MY, Yang H, Bergen J, Giachelli CM. Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. Arterioscler Thromb Vasc Biol. 2010;30: 321-326.
52. Sanchez-Niño MD, Bozic M, Córdoba-Lanús E, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2012;302:647-657.
53. Resnick LM, Müller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med. 1986;105:649-654.
54. Freundlich M, Quiroz Y, Zhang Z, et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008;74:1394-1402.
55. Park JW, Bae EH, Kim IJ, et al. Renoprotective effects of paricalcitol on gentamicin-induced kidney injury in rats. Am J Physiol Renal Physiol. 2010;298:301-313.
56. Sochorová K, Budinský V, Rozková D, et al. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol. 2009;133:69-77.
57. Ari E, Kedrah AE, Alahdab Y, et al. Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model. Br J Radiol. 2012;85:1038-1043.
58. Meems LM, Cannon MV, Mahmud H, et al. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol. 2012;132:282-289.
59. Husain K, Ferder L, Mizobuchi M, Finch J, Slatopolsky E. Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol. 2009;29:465-472.
60. Park JW, Cho JW, Joo SY, et al. Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation. Eur J Pharmacol. 2012;683:301-309.
61. Mizobuchi M, Morrissey J, Finch JL, et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol. 2007;18:1796-1806.
62. Husain K, Suarez E, Isidro A, Ferder L. Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am J Nephrol. 2010;32:296-304.
63. Kong J, Kim GH, Wei M, et al. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am J Pathol. 2010;177:622-631.
64. Mizobuchi M, Nakamura H, Tokumoto M, et al. Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol. 2010;121: 188-192.
65. Fraga C, Blanco M, Vigo E, et al. Autogenesis of the vitamin D receptor in the rat heart. Histochem Cell Biol. 2002;117:547-550.
66. Wu-Wong JR, Noonan W, Nakane M, et al. Vitamin d receptor activation mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats. Int J Endocrinol. Epub February 10, 2010.
67. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 2007;72:709-715.
68. Cardús A, Panizo S, Parisi E, Fernandez E, Valdivielso JM. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res. 2007;22:860-866.
69. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. Engl J Med. 31, 2003;349:446-456.
70. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006;70:1858-1865.
71. Cozzolino M, Brancaccio D, Cannella G, et al. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH, = 150 pg/mL: results of the Italian FARO Survey. Nephrol Dial Transplant. 2012;27(9):3588-3594.
72. He W, Kang YS, Dai C, Liu Y. Blockade of Wnt/?-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol. 2011;22:90-103.
73. Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P. The role of paricalcitol on proteinuria. J Ren Care. 2011;37:80-84.
74. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005;68:2823-2828.
75. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376:1543-1551.
76. Thadhani R, Appelbaum E, Pritchett Y. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307:674-684.